Publications
41
Citations
646
Est. group size
—
Recurring co-author estimate
Active years
14
Publishing since 2013
Typically publishes in teams of ~8 · 8% small-team papers (≤3 authors) · across 18 venues
- Re-Purposing Bispecific Antibodies in Autoimmune Diseases: MIDD Based Dose Optimization Strategies
2026
- Role of AI in drug development: Current status, challenges, opportunities, and future promise
Artificial Intelligence in Health · 2026
- De-risking Biopharma Asset Acquisition: Towards a Quantitative Framework for Strategic Decision-making
The AAPS Journal · 2026
- Advancing drug development with “Fit-for-Purpose” modeling informed approaches
Journal of Pharmacokinetics and Pharmacodynamics · 2025
- Exposure‐Response Relationships for Axatilimab in Patients with Chronic Graft‐Versus‐Host Disease
Clinical Pharmacology & Therapeutics · 2025
- Model-Informed Immunogenicity Assessment of Nivolumab as Monotherapy and in Combination with Ipilimumab
The AAPS Journal · 2025
- Effect of Itraconazole or Rifampin on Zilurgisertib Pharmacokinetics When Administered Orally in Healthy Participants
Clinical Pharmacology in Drug Development · 2025
- Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients With Solid Tumors or Chronic Graft‐Versus‐Host Disease
Clinical Pharmacology & Therapeutics · 2024
- Pharmacokinetics of Zilurgisertib With and Without Food from Single and Multiple Ascending Dose Phase 1 Studies in Healthy Adults
European Journal of Drug Metabolism and Pharmacokinetics · 2024
- Machine Learning in Predicting Longitudinal Platelet Counts: Applications in Dose Optimization
Blood · 2024
- Exposure-Response Relationships for Axatilimab, a Humanized Monoclonal Antibody Targeting CSF-1R, in Patients with Chronic Graft-Versus-Host Disease
Blood · 2024
- Evaluation of Itacitinib Impact on TNFα Levels Following Immune Effector Cell (IEC) Therapy Using PKPD Modeling and Simulation Approaches
Blood · 2024
- Population Pharmacokinetics/Pharmacodynamics Modeling of INCAGN02390 in Patients with Select Advanced Malignancies
2024
- Model Informed Drug Development (MIDD) Approach to Support Elzovantinib (TPX-022) Recommended Phase 2 Dose
2024
- Itacitinib Population Pharmacokinetics (PopPK) and Exposure-Response for Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy: Results From Phase 2 Study NCT04071366
2024
- Clinical Pharmacology & Therapeutics×4
- The Journal of Clinical Pharmacology×3
- CPT Pharmacometrics & Systems Pharmacology×3
- The AAPS Journal×3
- Annals of Oncology×3
- Xi Yang
Medicine · University of Michigan
- Nisha Nagarsheth
Medicine · University of Michigan
- Aditi Kulkarni
Medicine · University of Michigan
- Jennifer E. Kim
Medicine · The Ohio State University
- Jeremy Chang
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile